# Syndax Pharmaceuticals Inc: filings

SNDX · Nasdaq · CIK 1395937 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sndx.md) · [Financials](/companies/sndx/financials.md) · [Filings](/companies/sndx/filings.md) · [Insiders](/companies/sndx/insiders.md)

## Reports and events: 182 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 223, 8-K 114, SC 13G/A 44, 10-Q 32, 3 32, 144 25, SC 13G 20, 424B5 19, CT ORDER 11, S-8 11, 10-K 10, DEF 14A 10, D 9, DEFA14A 9, S-1/A 9, UPLOAD 8, CORRESP 7, DRS/A 6, SCHEDULE 13G/A 6, ARS 4, DRSLTR 3, EFFECT 3, S-3 3, SCHEDULE 13G 3, 10-K/A 2, 4/A 2, DRS 2, RW 2, S-1 2, S-3ASR 2, 424B4 1, 8-A12B 1, 8-K/A 1, CERTNAS 1, PRE 14A 1, SC 13D 1, SC 13D/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:04 ET | [10-Q](/filings/0001193125-26-332750.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332750 |
| 2026-08-04 | 16:02 ET | [8-K](/filings/0001193125-26-332736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332736 |
| 2026-07-14 | 08:30 ET | [8-K](/filings/0001193125-26-302608.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-302608 |
| 2026-06-10 | 17:04 ET | [8-K](/filings/0001193125-26-266027.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-266027 |
| 2026-06-10 | 16:15 ET | [8-K](/filings/0001193125-26-265852.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265852 |
| 2026-06-04 | 07:16 ET | [8-K](/filings/0001193125-26-256458.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-256458 |
| 2026-04-30 | 17:20 ET | [DEF 14A](/filings/0001193125-26-197859.md) | Proxy statement, period 2026-04-30 | 0001193125-26-197859 |
| 2026-04-30 | 16:04 ET | [10-Q](/filings/0001193125-26-197154.md) | Quarterly report, period 2026-03-31 | 0001193125-26-197154 |
| 2026-04-30 | 16:02 ET | [8-K](/filings/0001193125-26-197124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197124 |
| 2026-02-26 | 16:04 ET | [10-K](/filings/0001193125-26-076536.md) | Annual report, period 2025-12-31 | 0001193125-26-076536 |
| 2026-02-26 | 16:02 ET | [8-K](/filings/0001193125-26-076522.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076522 |
| 2026-01-12 | 16:36 ET | [8-K](/filings/0001193125-26-010486.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001193125-26-010486 |
| 2025-12-19 | 16:30 ET | [8-K](/filings/0001193125-25-326961.md) | 5.03 Amendment to articles or bylaws | 0001193125-25-326961 |
| 2025-11-03 | 16:04 ET | [10-Q](/filings/0001193125-25-262521.md) | Quarterly report, period 2025-09-30 | 0001193125-25-262521 |
| 2025-11-03 | 16:02 ET | [8-K](/filings/0001193125-25-262509.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-262509 |
| 2025-10-24 | 16:40 ET | [8-K](/filings/0001193125-25-250052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250052 |
| 2025-08-04 | 16:05 ET | [10-Q](/filings/0000950170-25-101985.md) | Quarterly report, period 2025-06-30 | 0000950170-25-101985 |
| 2025-08-04 | 16:02 ET | [8-K](/filings/0000950170-25-101974.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-101974 |
| 2025-06-26 | 08:54 ET | [8-K](/filings/0000950170-25-090205.md) | 5.02 Departure or appointment of officers or directors | 0000950170-25-090205 |
| 2025-05-16 | 16:15 ET | [8-K](/filings/0000950170-25-073555.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-073555 |
| 2025-05-05 | 16:04 ET | [10-Q](/filings/0000950170-25-063518.md) | Quarterly report, period 2025-03-31 | 0000950170-25-063518 |
| 2025-05-05 | 16:02 ET | [8-K](/filings/0000950170-25-063514.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-063514 |
| 2025-04-01 | 16:01 ET | [DEF 14A](/filings/0000950170-25-048472.md) | Proxy statement, period 2025-04-01 | 0000950170-25-048472 |
| 2025-03-03 | 07:05 ET | [10-K](/filings/0000950170-25-030394.md) | Annual report, period 2024-12-31 | 0000950170-25-030394 |
| 2025-03-03 | 07:02 ET | [8-K](/filings/0000950170-25-030392.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-030392 |
| 2024-12-20 | 17:00 ET | [8-K](/filings/0000950170-24-139121.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-139121 |
| 2024-11-18 | 17:41 ET | [8-K](/filings/0000950170-24-127708.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-127708 |
| 2024-11-12 | 07:05 ET | [8-K](/filings/0000950170-24-124545.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-124545 |
| 2024-11-05 | 16:03 ET | [10-Q](/filings/0000950170-24-121439.md) | Quarterly report, period 2024-09-30 | 0000950170-24-121439 |
| 2024-11-05 | 16:02 ET | [8-K](/filings/0000950170-24-121437.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-121437 |
| 2024-11-04 | 16:05 ET | [8-K](/filings/0000950170-24-120673.md) | 1.01 Entry into a material agreement | 0000950170-24-120673 |
| 2024-08-01 | 16:04 ET | [10-Q](/filings/0000950170-24-089241.md) | Quarterly report, period 2024-06-30 | 0000950170-24-089241 |
| 2024-08-01 | 16:02 ET | [8-K](/filings/0000950170-24-089235.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-089235 |
| 2024-05-15 | 16:11 ET | [8-K](/filings/0000950170-24-060462.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-060462 |
| 2024-05-08 | 07:04 ET | [10-Q](/filings/0000950170-24-055053.md) | Quarterly report, period 2024-03-31 | 0000950170-24-055053 |
| 2024-05-08 | 07:03 ET | [8-K](/filings/0000950170-24-055052.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055052 |
| 2024-04-02 | 16:00 ET | [DEF 14A](/filings/0000950170-24-040099.md) | Proxy statement, period 2024-03-27 | 0000950170-24-040099 |
| 2024-03-18 | 07:10 ET | [8-K](/filings/0000950170-24-032514.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-032514 |
| 2024-02-27 | 16:33 ET | [10-K](/filings/0000950170-24-021253.md) | Annual report, period 2023-12-31 | 0000950170-24-021253 |
| 2024-02-27 | 16:03 ET | [8-K](/filings/0000950170-24-021086.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-021086 |
| 2023-12-20 | 08:40 ET | [8-K](/filings/0000950170-23-071749.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-071749 |
| 2023-12-15 | 17:29 ET | [8-K](/filings/0001193125-23-296814.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-23-296814 |
| 2023-12-12 | 16:05 ET | [8-K](/filings/0000950170-23-069683.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-069683 |
| 2023-11-02 | 16:05 ET | [10-Q](/filings/0000950170-23-058165.md) | Quarterly report, period 2023-09-30 | 0000950170-23-058165 |
| 2023-11-02 | 16:03 ET | [8-K](/filings/0000950170-23-058156.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-058156 |
| 2023-10-02 | 07:04 ET | [8-K](/filings/0000950170-23-050922.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-050922 |
| 2023-08-03 | 16:06 ET | [10-Q](/filings/0000950170-23-037943.md) | Quarterly report, period 2023-06-30 | 0000950170-23-037943 |
| 2023-08-03 | 16:04 ET | [8-K](/filings/0000950170-23-037936.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037936 |
| 2023-07-24 | 07:07 ET | [8-K](/filings/0000950170-23-033937.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-033937 |
| 2023-05-26 | 16:47 ET | [8-K](/filings/0000950170-23-024544.md) | 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-024544 |

Page 1 of 4. [Older](/companies/sndx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 19:11 ET. No prices; not investment advice.